ArticleAging clinical and experimental research2026
Biological age-acceleration in relation to muscle mass, strength and function: findings from the Hertfordshire Cohort Study.
Article in Aging clinical and experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSarcopenia, the accelerated loss of muscle mass, strength and function with age, is associated with adverse health outcomes. DNA methylation accumulates across life and methylation clocks (which provide a measure of biological age) could potentially be used to predict individuals at high sarcopenia risk. In this study, we examined biological age-acceleration measures in relation to sarcopenia components.
methodsOverall, 331 participants from the UK community-dwelling Hertfordshire Cohort Study were analysed. At baseline (1998-2004), participants underwent health assessments and provided blood samples. At follow-up (2011-12), appendicular lean mass (ALM) index was ascertained using DXA; muscle strength by grip dynamometry; and gait speed over 8ft (2.44 m). DNA was extracted from peripheral blood leukocytes and DNA methylation at CpG sites was measured using the Infinium Human Methylation Beadchip array. Methylation clock measures were ascertained, and examined in relation to grip strength, gait speed and ALM index using linear regression, and in relation to a sarcopenia score (number of sarcopenia components) using Poisson regression. Baseline age, follow-up time, height and BMI were included as adjustments.
resultsAt baseline, mean (SD) age was 65.1 (2.8) years. Among males, greater age-acceleration was related to lower grip strength; the standard deviation (SD) difference in grip strength per SD increase in age-acceleration was - 0.16 (-0.32, -0.01) for Principal Component (PC) PhenoAge and - 0.16 (-0.31, -0.01) for bAge. Associations regarding grip strength among females, and for gait speed and ALM index among both males and females were weak. The multiplicative increase in sarcopenia score per SD increase in age-acceleration among females was 1.23 (1.04, 1.45) for PCHorvath1, and 1.20 (1.02, 1.41) for PCHorvath2 (p = 0.02 for both associations).
conclusionsGreater age-acceleration was related to lower grip strength among males only, and associations regarding gait speed and ALM index were weak among both sexes. Greater baseline biological age-acceleration was related to a higher sarcopenia score among females. These findings require further investigation in larger cohorts.
Indexed as
Identifiers
42471507What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.